
Abstract Objectives To characterize the clinical phenotype and long‐term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. Methods Multicenter observational case‐control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric‐onset IBD (<18 years) between 2009 and 2024 were included. Syndromic cases were matched 1:2 with non‐syndromic controls by gender, age at diagnosis, IBD type, and follow‐up duration. Demographic, clinical, and therapeutic data were analyzed. Results Sixty‐nine patients were included (23 syndromic and 46 controls). At diagnosis, syndromic patients had lower weight (−1.16 z‐score, p = 0.004) and height (−1.43 z ‐score, p < 0.001); these differences persisted at follow‐up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation ( p = 0.01). Syndromic patients had more hospitalizations (IBD‐related incidence rate ratio [IRR] 1.23, p = 0.033; non‐IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non‐IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. Conclusions Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non‐syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.
Abstract Objectives The role of immune checkpoint molecules (ICMs) in celiac disease (CD) remains incompletely understood despite their expected function in limiting mucosal immune–mediated injury. This study aimed to evaluate duodenal PD‐1 and PD‐L1 expression in pediatric duodenal samples, investigate associations with histologic/serologic activity, and assess their diagnostic performance. Methods Patients' files who applied to the pediatric gastroenterology clinic and underwent esophagogastroduodenoscopy between 01.01.2022 and 31.12.2023 were retrospectively reviewed. CD was defined by European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)‐based clinicopathologic correlation. PD‐1/PD‐L1 immunohistochemistry was quantified as the number of positive mononuclear cells per HPF (40x) in the lamina propria in hot spot areas. The diagnostic potential in differentiating CD and non‐CD cases was investigated with receiver operating characteristics (ROC) analysis. Results A total of 142 children (mean age 10.3 ± 4.4 years; 64.8% male); 68 (47.9%) had CD, and 74 (52.1%) served as non‐CD controls. Both markers were significantly elevated in CD tissues ( p < 0.001). In ROC analysis, PD‐L1 outperformed PD‐1 for identifying CD (area under the curve: 0.933 vs. 0.809). A PD‐L1 > 6.5/HPF cut‐off yielded 92.6% sensitivity and 83.8% specificity. PD‐L1 was associated with an increase in Marsh grade in CD samples ( p = 0.033) and with an increase in IEL in non‐CD cases ( p = 0.016). Conclusion PD‐1 and PD‐L1 are specifically increased in CD, and PD‐L1 could be a candidate diagnostic marker for CD. In autoimmune disorders such as CD, elucidating the interactions, functional capacities, and degrees of involvement of these molecules can provide insights into the pathogenesis, diagnosis, and treatment.
OBJECTIVES: Pancreatic involvement in inflammatory bowel disease (IBD) represents a heterogeneous group of conditions. Our study assessed the prevalence of hyperlipasemia and pancreatic imaging involvement in children with newly diagnosed IBD. We also evaluated predictors of pancreatic changes on magnetic resonance imaging in this population. METHODS: This retrospective study analysed the standard magnetic resonance enterography (MRE) protocol with additional sequences for pancreatic assessment. The serum activity of lipase, aminotransferases, and total immunoglobulin G (IgG) and its subclasses concentrations were measured at diagnosis, as well as body mass index percentile (pBMI) and IBD activity. RESULTS: Data from 68 children were analysed. Increased IgG concentrations were observed in 25 patients (36.6%) for total IgG and in 25 patients (36.6%) for IgG1. Among 27 patients (39.7%) with increased lipase, 8 (29.6%) had increased IgG concentration and 10 (37.1%) had increased IgG1 concentration; both IgG and IgG1 concentration were elevated in 7 (87.5%) patients. MRE revealed pancreatic involvement in 20.59%. Patients with pancreatic involvement on MRE had higher total IgG (p = 0.012) and IgG1 (p = 0.024) levels and lipase activity 3x higher than the normal limit (p = 0.04). Total IgG and IgG1 concentrations were significantly associated with MRE findings and their combination yielded the highest discriminatory performance. IgG subclasses proved to be useful in a multivariate model incorporating IgG1 and IgG2 concentrations (0.75; 95% confidence interval: 0.59-0.92). CONCLUSION: Structural pancreatic involvement was observed in one-fifth of our patients. They had significantly higher total IgG and IgG1 levels. The IgG1 + IgG2 model performed best in prediction pancreatic MRE changes.
OBJECTIVES: Paediatric liver transplantation (pLT) is associated with excellent long-term survival and quality of life. As a growing proportion of recipients survive into adulthood, long-term follow-up after transfer from paediatric to adult care is increasingly important. We aimed to describe patient and graft survival, retention in care, adherence, medical complications and achievement of an ideal outcome after transfer of care. METHODS: This prospective observational study included all pLT recipients who entered our centre's transition programme between January 2010 and December 2024. Prespecified outcomes included patient and graft survival, retention in adult care, attendance and medication adherence, a composite non-adherence outcome, post-transfer medical complications and the proportion achieving an ideal outcome at predefined timepoints. RESULTS: Sixty patients were included (53.3% male; median age at pLT 5 [2.1-10.4] years; median age at transfer of care 19.8 [interquartile range (IQR) 18.9-24] years). Patient survival at 1, 5, 10 and 15 years after transfer of care was 98%, 96%, 93% and 93%, while graft survival was 98%, 94%, 91% and 75%, respectively. At the time of transfer of care, 55% of patients fulfilled criteria for an ideal outcome; this decreased to 41.6% at 5 years and 25% at 10 years. Medication non-adherence was documented in 20%, and composite non-adherence in 25%. The tacrolimus Medication Level Variability Index was significantly associated with composite non-adherence (p = 0.007) and was higher in patients who developed chronic rejection than in those who did not (p = 0.05). CONCLUSIONS: Despite excellent long-term survival, pLT recipients reaching adulthood face increasing challenges over time, particularly regarding adherence. These descriptive findings support continued, individualised follow-up after transfer to adult healthcare.